Biosimilar Administration Considerations Impacting Patient Experience

EP: 1.Utilizing Recently Approved Biosimilars in Clinical Practice

EP: 2.Transitioning to Biosimilars: Considerations for Providers and Payers

EP: 3.Navigating Challenges Associated with Biosimilars Across Various Disease States

EP: 4.Provider Acceptance Driving Confidence in Biosimilar Therapy

EP: 5.Decision-Making Process Surrounding Biosimilar Implementation

Now Viewing

EP: 6.Biosimilar Administration Considerations Impacting Patient Experience

EP: 7.Initiating Biosimilar Treatment in Patients Without Previous Reference Biologic Experience

EP: 8.Switching Patients from Reference Product to Biosimilar

EP: 9.Defining Interchangeability and Switching in Biologics

EP: 10.Evolution of Auto-Substitution in Biosimilar Landscape

EP: 11.An Overview of Biosimilar Extrapolation During FDA Approval

EP: 12.Harnessing Indication-Specific Data on Biosimilars

EP: 13.Cost Savings Related to Biosimilars

EP: 14.Payers and PBMs Impacted by Biosimilar Integration

EP: 15.Payer Support Driving Lowering of Biosimilar-Related Health Care Costs

EP: 16.Patient Conversations: Managing Patient Expectations Regarding Biosimilars

EP: 17.Key Points of Emphasis Regarding Biosimilar Integration

This is a video synopsis/summary of a panel discussion involving a multidisciplinary team of experts: Ryan Haumschild, PharmD, MS, MBA; Alice B. Gottlieb, MD, PhD; Bincy Abraham, MD, MS; Jamie T. Brogan, APRN; and Vibeke Strand, MD. The discussion delves into critical aspects of rheumatologic treatment strategies, providing valuable insights into evolving practices.

Haumschild initiates the discourse by emphasizing the advancements in biosimilars, focusing particularly on adalimumab (Humira). The discussion centers on concentration differences, with a spotlight on FDA-approved biosimilars featuring varying strengths. This prompts Brogan to elaborate on the practical implications, such as altered dosing regimens and the resultant impact on patient adherence. The transition to higher concentrations, notably in the gastrointestinal setting, emerges as a game-changer, reducing barriers and improving the overall patient experience.

The conversation takes an intriguing turn as Gottlieb sheds light on challenges in dermatology, addressing specifically hidradenitis suppurativa. Gottlieb introduces the off-label use of infliximab (Remicade), highlighting its potential efficacy in weight-based dosing. Notably, Strand brings attention to the differences in practice settings, emphasizing rheumatologists’ preference for self-administered subcutaneous therapies due to reimbursement issues associated with intravenous treatments.

Abraham underscores the significance of concentration in patient care, particularly in the context of gastrointestinal conditions. The transition to higher concentrations proves beneficial in addressing obstacles associated with invasive weekly medications.

Video synopsis is AI-generated and reviewed by AJMC editorial staff.